4169 Stock Overview
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TCM Biotech International Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$55.70 |
| 52 Week High | NT$71.41 |
| 52 Week Low | NT$48.52 |
| Beta | 0.046 |
| 1 Month Change | 5.29% |
| 3 Month Change | -2.28% |
| 1 Year Change | 12.56% |
| 3 Year Change | 81.95% |
| 5 Year Change | 148.07% |
| Change since IPO | 94.27% |
Recent News & Updates
Recent updates
Can You Imagine How TCM Biotech International's (GTSM:4169) Shareholders Feel About The 28% Share Price Increase?
Jan 31
Key Things To Consider Before Buying TCM Biotech International Corp. (GTSM:4169) For Its Dividend
Jan 04We Think TCM Biotech International (GTSM:4169) Can Stay On Top Of Its Debt
Dec 07
Shareholder Returns
| 4169 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 10.1% | -1.6% | -2.3% |
| 1Y | 12.6% | -22.6% | 27.2% |
Return vs Industry: 4169 exceeded the TW Biotechs industry which returned -22.6% over the past year.
Return vs Market: 4169 underperformed the TW Market which returned 27.2% over the past year.
Price Volatility
| 4169 volatility | |
|---|---|
| 4169 Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4169 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4169's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Ya-Chun Wang | www.tcmbio.com |
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company’s products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
TCM Biotech International Corp. Fundamentals Summary
| 4169 fundamental statistics | |
|---|---|
| Market cap | NT$3.29b |
| Earnings (TTM) | NT$18.57m |
| Revenue (TTM) | NT$969.62m |
177.1x
P/E Ratio3.4x
P/S RatioIs 4169 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4169 income statement (TTM) | |
|---|---|
| Revenue | NT$969.62m |
| Cost of Revenue | NT$489.45m |
| Gross Profit | NT$480.17m |
| Other Expenses | NT$461.59m |
| Earnings | NT$18.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 49.52% |
| Net Profit Margin | 1.92% |
| Debt/Equity Ratio | 10.3% |
How did 4169 perform over the long term?
See historical performance and comparison